News & Publications


"We are focused on delivering a genomic framework for personalized medicine using biological information to inform the radiation treatment parameters. This technology allows us to predict which patients benefit from radiation more than others allowing for the personalization of radiation therapy." 
— Javier Torres-Roca, MD



Moffitt Cancer Center & Research Institute

Date Here, 2017

Here is a description of your PR. Nullam tempor dolor sed nulla auctor, nec placerat felis sodales. Etiam et turpis mattis, efficitur mi ut, ultrices diam. Donec consectetur, odio eget porta varius, orci mauris viverra ante, eget egestas turpis sapien vel orci. Donec eu ornare augue, ut. READ FULL PRESS RELEASE 


Cvergenx, Inc. Brings Radiation Oncology into the Era of Individualized Medicine

January 4th, 2017

Tampa, FL — In an endeavor to bring radiation oncology into the era of individualized medicine, Cvergenx, Inc. today reaffirmed its plans to commercialize the first genomics-driven approach to precision radiation therapy. This advance, recently recognized by The Lancet Oncology, one the most widely read and well respected peer-reviewed oncology journals in the world today, was echoed in an editorial commentary in the same publication. READ FULL PRESS RELEASE 

Cvergenx Co-Founder and Moffitt Researchers Discover Liver Metastases Have Different Radiation Sensitivities

April 18, 2016

Tampa, FL — Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor. READ FULL PRESS RELEASE 

Journal of the National Cancer Institute Reports That Genetic Testing of Tumors is Driving Personalized Medicine in Radiation Oncology

December 11, 2015

In a recent article published in the Journal of the National Cancer Institute, Sue Rochman interviews the co-founder of Cvergenx Inc. regarding a recent study that used a molecular assay to assess the radiation sensitivity of primary tumors and metastases suggesting potential for genetic testing in guiding radiation therapy. READ FULL ARTICLE →